60 DEGREES PHARMACEUTICALS INC. - COMMON STOCK

0.3490

10-June-24 15:59:46

15 minutes delayed

Stocks

-0.0020

-0.57%

Today's range

0.3000 - 0.3990

ISIN

N/A

Source

NASDAQ

60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity

30 Aug 2023 07:32:00 By Nasdaq GlobeNewswire
60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum Malaria

22 Aug 2023 07:31:00 By Nasdaq GlobeNewswire
60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.gov

15 Aug 2023 07:31:00 By Nasdaq GlobeNewswire
60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive Subjects

31 Jul 2023 07:59:00 By Nasdaq GlobeNewswire
60 Degrees Pharmaceuticals Announces Closing of Initial Public Offering

14 Jul 2023 12:39:27 By Nasdaq GlobeNewswire
60 Degrees Pharmaceuticals Announces Pricing of Initial Public Offering

12 Jul 2023 12:29:58 By Nasdaq GlobeNewswire

<<
<
1
2
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.